CHMP recommends EU approval of Roche’s subcutaneous Herceptin for HER2 positive breast cancer
28 June 2013 | By Roche
"Over the last 14 years, Herceptin has revolutionised the treatment of HER2-positive breast cancer..."
List view / Grid view
News
GSK’s drisapersen to receive FDA breakthrough therapy designation for potential treatment of patients with DMD
27 June 2013 | By GlaxoSmithKline
GlaxoSmithKline has received a verbal notification...
GSK and Save the Children launch $1 million award to discover new healthcare innovations for reducing child deaths
27 June 2013 | By GSK
GSK and Save the Children today launched a $1 million Healthcare Innovation Award...
Rapid Micro Biosystems secures $32.6 million in series B financing
26 June 2013 | By Rapid Micro Biosystems
Rapid Micro Biosystems announced that it has raised $32.6 million in series B financing...
Novartis reports new Phase III data showing omalizumab significantly improves itch in patients with severe form of chronic skin disease CSU[1]
26 June 2013 | By Novartis
Novartis announced late-breaking results...
Rigaku Raman delivers new software enhancements to its Xantus-2 portable analyzer
25 June 2013 | By Rigaku
Rigaku Raman Technologies has announced software enhancements to its leading Xantus-2™ dual-wavelength portable Raman analyzer...
Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at ADA
25 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with an increased risk of cardiovascular events in the treatment of Type 2 Diabetes (T2D), versus a number of…
GSK announces data from five Phase III studies of albiglutide
24 June 2013 | By GlaxoSmithKline
Data from five long-term Phase III studies comparing albiglutide...
Global study finds one in five feel discriminated against because of their diabetes
24 June 2013 | By Novo Nordisk
Key results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™)...
Sandoz launches Phase III clinical trial for biosimilar etanercept
24 June 2013 | By Novartis
Sandoz has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen's Enbrel®)...
Application submitted to the EMA for use of Pradaxa® in treatment of DVT and PE and prevention of recurrent DVT and PE
24 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the submission of an application to the EMA...
New retrospective analysis supports clinical data – Victoza® provides improved blood sugar control compared to sitagliptin and exenatide
22 June 2013 | By Novo Nordisk
Findings from a new real-world study...
Sanofi announces positive Phase 3 results for investigational new insulin U300
22 June 2013 | By Sanofi
Topline results of EDITION II consistent with EDITION I findings...
Dolomite expertise brings microfluidic product to market
21 June 2013 | By kdm communications limited
Fledgling spin-out company Drop-Tech has turned to microfluidics specialist Dolomite for its product development and fabrication skills...
FDA grants breakthrough therapy designation to Novartis’ serelaxin (RLX030) for acute heart failure
21 June 2013 | By Novartis
RLX030 has the potential to address a serious unmet medical need...
